{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:24:16Z","timestamp":1768083856868,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00404-020-05489-3","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T13:02:47Z","timestamp":1584450167000},"page":"1047-1054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Advanced stage primary mucinous ovarian carcinoma. Where do we stand ?"],"prefix":"10.1007","volume":"301","author":[{"given":"Dimitrios","family":"Nasioudis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin B.","family":"Albright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley F.","family":"Haggerty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Robert L.","family":"Giuntoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawar A.","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"issue":"9 Suppl 3","key":"5489_CR1","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/IGC.0000000000000296","volume":"24","author":"JA Ledermann","year":"2014","unstructured":"Ledermann JA, Luvero D, Shafer A et al (2014) Gynecologic cancer intergroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer 24(9 Suppl 3):S14\u2013S29","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"5489_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11912-014-0389-x","volume":"16","author":"J Brown","year":"2014","unstructured":"Brown J, Frumovitz M (2014) Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep 16(6):389","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"5489_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/PAS.0b013e3180690d2d","volume":"32","author":"AV Yemelyanova","year":"2008","unstructured":"Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM (2008) Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 32(1):128\u2013138","journal-title":"Am J Surg Pathol"},{"issue":"Suppl 1","key":"5489_CR4","doi-asserted-by":"publisher","first-page":"i53","DOI":"10.1093\/annonc\/mdw087","volume":"27","author":"TJ Perren","year":"2016","unstructured":"Perren TJ (2016) Mucinous epithelial ovarian carcinoma. Ann Oncol 27(Suppl 1):i53\u2013i57","journal-title":"Ann Oncol"},{"issue":"3","key":"5489_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/cncr.25453","volume":"117","author":"RA Soslow","year":"2011","unstructured":"Soslow RA (2011) Mucinous ovarian carcinoma: slippery business. Cancer 117(3):451\u2013453","journal-title":"Cancer"},{"issue":"3","key":"5489_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ygyno.2018.01.035","volume":"149","author":"EK Crane","year":"2018","unstructured":"Crane EK, Brown J (2018) Early stage mucinous ovarian cancer: a review. Gynecol Oncol 149(3):598\u2013604","journal-title":"Gynecol Oncol"},{"issue":"5","key":"5489_CR7","doi-asserted-by":"publisher","first-page":"480.e1","DOI":"10.1016\/j.ajog.2011.06.049","volume":"205","author":"MB Schiavone","year":"2011","unstructured":"Schiavone MB, Herzog TJ, Lewin SN et al (2011) Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 205(5):480.e1\u20138","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"5489_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/IGC.0000000000000932","volume":"27","author":"M Simons","year":"2017","unstructured":"Simons M, Massuger L, Bruls J et al (2017) Relatively poor survival of mucinous ovarian carcinoma in advanced stage: a systematic review and meta-analysis. Int J Gynecol Cancer 27(4):651\u2013658","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"5489_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP et al (2008) The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15(3):683\u2013690","journal-title":"Ann Surg Oncol"},{"key":"5489_CR10","unstructured":"Mackay HJ, Brady MF, Oza AM et al (2010) Gynecologic Cancer InterGroup. Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer. Int J Gynecol Cancer 20(6):945\u2013952."},{"issue":"3","key":"5489_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ygyno.2018.07.013","volume":"150","author":"NS Meagher","year":"2018","unstructured":"Meagher NS, Schuster K, Voss A et al (2018) Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. Gynecol Oncol 150(3):527\u2013533","journal-title":"Gynecol Oncol"},{"key":"5489_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/cncr.25460","volume":"117","author":"RJ Zaino","year":"2011","unstructured":"Zaino RJ, Brady MF, Lele SM et al (2011) Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 117:554\u2013562","journal-title":"Cancer"},{"issue":"7","key":"5489_CR13","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/IGC.0000000000000473","volume":"25","author":"M Simons","year":"2015","unstructured":"Simons M, Ezendam N, Bulten J, Nagtegaal I, Massuger L (2015) Survival of patients with mucinous ovarian carcinoma and ovarian metastases: a population-based cancer registry study. Int J Gynecol Cancer 25(7):1208\u20131215","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"5489_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ygyno.2004.12.056","volume":"97","author":"D Pectasides","year":"2005","unstructured":"Pectasides D, Fountzilas G, Aravantinos G et al (2005) Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 97(2):436\u2013441","journal-title":"Gynecol Oncol"},{"issue":"12","key":"5489_CR15","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdq257","volume":"21","author":"J Alexandre","year":"2010","unstructured":"Alexandre J, Ray-Coquard I, Selle F et al (2010) Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol 21(12):2377\u20132381","journal-title":"Ann Oncol"},{"issue":"6","key":"5489_CR16","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","volume":"22","author":"V Hess","year":"2004","unstructured":"Hess V, A'Hern R, Nasiri N et al (2004) Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22(6):1040\u20131044","journal-title":"J Clin Oncol"},{"issue":"9","key":"5489_CR17","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.6004\/jnccn.2016.0122","volume":"14","author":"RJ Morgan Jr","year":"2016","unstructured":"Morgan RJ Jr, Armstrong DK, Alvarez RD et al (2016) Ovarian cancer, version 1: 2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14(9):1134\u20131163","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"5489_CR18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/IGC.0000000000001263","volume":"28","author":"JJ Mueller","year":"2018","unstructured":"Mueller JJ, Lajer H, Mosgaard BJ et al (2018) International study of primary mucinous ovarian carcinomas managed at tertiary medical centers. Int J Gynecol Cancer 28(5):915\u2013924","journal-title":"Int J Gynecol Cancer"},{"issue":"Supplement 1","key":"5489_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ygyno.2018.04.531","volume":"149","author":"B Schlappe","year":"2018","unstructured":"Schlappe B, Zhou Q, O'Cearbhaill R et al (2018) Comparison of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen. Gynecol Oncol 149(Supplement 1):236","journal-title":"Gynecol Oncol"},{"key":"5489_CR20","unstructured":"Gore ME, Hackshaw A, Brady WE et al (2015) Multicentre trial of carboplatin\/paclitaxel versus oxaliplatin\/capecitabine, each with\/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC). As presented at the 2015 ASCO Annual Meeting. https:\/\/meetinglibrary.asco.org\/content\/145864-156 (abstract 5528)."},{"issue":"4","key":"5489_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1200\/JCO.2014.55.3107","volume":"33","author":"JL Warren","year":"2015","unstructured":"Warren JL, Butler EN, Stevens J et al (2015) Receipt of chemotherapy among medicare patients with cancer by type of supplemental insurance. J Clin Oncol 33(4):312\u2013318","journal-title":"J Clin Oncol"},{"issue":"3","key":"5489_CR22","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1245\/s10434-017-6310-8","volume":"25","author":"M Reghunathan","year":"2018","unstructured":"Reghunathan M, Kelly KJ, Valasek MA, Lowy AM, Baumgartner JM (2018) Histologic predictors of recurrence in mucinous appendiceal tumors with peritoneal dissemination after HIPEC. Ann Surg Oncol 25(3):702\u2013708","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"5489_CR23","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1245\/s10434-018-6464-z","volume":"25","author":"F Mercier","year":"2018","unstructured":"Mercier F, Bakrin N, Bartlett DL et al (2018) Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol 25(6):1668\u20131675","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"5489_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2018.05.008","volume":"150","author":"JJ Mueller","year":"2018","unstructured":"Mueller JJ, Schlappe BA, Kumar R et al (2018) Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. Gynecol Oncol 150(1):127\u2013135","journal-title":"Gynecol Oncol"},{"issue":"1","key":"5489_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/PGP.0000000000000302","volume":"36","author":"RAA Mohammed","year":"2017","unstructured":"Mohammed RAA, Makboul R, Elsers DAH et al (2017) Pattern of HER-2 gene amplification and protein expression in benign, borderline, and malignant ovarian serous and mucinous neoplasms. Int J Gynecol Pathol 36(1):50\u201357","journal-title":"Int J Gynecol Pathol"},{"key":"5489_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/1471-2407-9-433","volume":"9","author":"JN McAlpine","year":"2009","unstructured":"McAlpine JN, Wiegand KC, Vang R et al (2009) HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9:433","journal-title":"BMC Cancer"},{"issue":"5","key":"5489_CR27","first-page":"1336","volume":"27","author":"N Sato","year":"2012","unstructured":"Sato N, Saga Y, Mizukami H et al (2012) Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations. Oncol Rep 27(5):1336\u20131340","journal-title":"Oncol Rep"},{"issue":"16","key":"5489_CR28","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-10-3176","volume":"17","author":"K Matsuo","year":"2011","unstructured":"Matsuo K, Nishimura M, Bottsford-Miller JN et al (2011) Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res 17(16):5367\u20135378","journal-title":"Clin Cancer Res"},{"issue":"23","key":"5489_CR29","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1158\/1078-0432.CCR-13-1305","volume":"19","author":"T Liu","year":"2013","unstructured":"Liu T, Hu W, Dalton HJ et al (2013) Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res 19(23):6532\u20136543","journal-title":"Clin Cancer Res"},{"issue":"20","key":"5489_CR30","doi-asserted-by":"publisher","first-page":"29577","DOI":"10.18632\/oncotarget.8807","volume":"7","author":"K Inaba","year":"2016","unstructured":"Inaba K, Oda K, Aoki K et al (2016) Synergistic antitumor effects of combination PI3K\/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging. Oncotarget 7(20):29577\u201329591","journal-title":"Oncotarget"},{"issue":"7","key":"5489_CR31","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ejca.2012.12.004","volume":"49","author":"K Muyldermans","year":"2013","unstructured":"Muyldermans K, Moerman P, Amant F et al (2013) Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. Eur J Cancer 49(7):1600\u20131608","journal-title":"Eur J Cancer"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05489-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-020-05489-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05489-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:25:48Z","timestamp":1615940748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-020-05489-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["5489"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05489-3","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"21 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no potential conflict of interest, including and financial or personal relationship which could be viewed as one.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The National Cancer Database is available to the public for research purpose. All patient data are de-identified. The present study was deemed exempt by the institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}